Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2024 Financial Results on August 15, 2023

Rhea-AI Impact
Rhea-AI Sentiment
conferences earnings
Rhea-AI Summary
Analysis in progress...
  • None.
  • None.

Financials for First Quarter Fiscal Year 2024 Ended June 30, 2023 will be released on August 14, 2023

NORTHVALE, NJ / ACCESSWIRE / August 9, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2024 fiscal year will be released on Monday, August 14, 2023. Elite's management will host a live conference call on Tuesday, August 15th, at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update. Stockholders should submit questions to the company before the call.

Date:August 15, 2023
Time:11:30 AM EDT
Dial-in numbers:1-800-346-7359 (domestic)
1-973-528-0008 (international)
Conference number:98840
General questions by 5:00 PM EDT on Saturday, August 12, 2023
Financial questions by 7:00 PM EDT on Monday, August 14, 2023
Audio Replay:

About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products, some of which are licensed to Prasco, LLC and TAGI Pharma. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.


For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222

SOURCE: Elite Pharmaceuticals, Inc.

View source version on

Elite Pharmaceuticals, Inc.


ELTP Rankings

ELTP Latest News

ELTP Stock Data

Pharmaceutical Preparation Manufacturing
Pharmaceuticals: Generic, Health Technology, Manufacturing, Pharmaceutical Preparation Manufacturing

About ELTP

elite pharmaceuticals, inc. develops oral sustained and controlled release products. elite's strategy includes assisting partner companies in the life cycle management of products, to improve off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. elite has four anda products partnered with tagi pharma; one anda has launched, two andas are in the process of a manufacturing site transfer and an additional anda is currently under review by the fda. elite also manufactures lodrane d® and receives royalties for lodrane d®, an allergy product partnered with ecr pharmaceuticals (“ecr”), a wholly owned subsidiary of hi-tech pharmacal (“hi-tech”). elite’s lead pipeline products, eli-216, a once-daily abuse resistant oxycodone, and eli-154, a once-daily oxycodone, are novel sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provisio